ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Prevalence of Elevated Lipoprotein(a) and Its Association with Cardiovascular Disease in Patients with Overweight and Obesity in Argentina.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lipoprotein(a) [Lp(a)] is an established independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Although both obesity and elevated Lp(a) are highly prevalent, their interrelationship and combined impact on ischemic heart disease (IHD) remain incompletely understood, particularly in Latin American populations. Objective: To evaluate the distribution of elevated Lp(a) across body mass index (BMI) categories, assess its association with ischemic heart disease (IHD), and determine whether this association differs across BMI categories. Methods: We conducted a multicenter observational study including 2975 adults from specialized centers in Argentina. Patients were stratified into BMI categories: Group 1: <25, Group 2 BMI: 25-29.9, Group 3: 30-34.9 kg/m Results: Median Lp(a) levels decreased across higher BMI categories. The prevalence of elevated Lp(a) declined across increasing BMI categories (34.6% in BMI <25 kg/m Conclusions: In this cross-sectional study, elevated Lp(a) was associated with prevalent ischemic heart disease across BMI categories despite lower crude prevalence among individuals with higher BMI. Because of the observational cross-sectional design, causal inferences cannot be made. Nevertheless, these findings support consideration of Lp(a) assessment across the BMI spectrum.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.